DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress in triple-negative breast cancer
R. Moreno, S. Banerjee, A. W. Jackson, J. Quinn, G. Baillie, J. E. Dixon, A. T. Dinkova-Kostova, J. Edwards, L. de la Vega
Abstract
To survive aneuploidy-induced proteotoxic stress, cancer cells activate the proteotoxic-stress response pathway, which is controlled by heat shock factor 1 (HSF1). This pathway supports cancer initiation, cancer progression and chemoresistance and thus is an attractive target. As developing HSF1 inhibitors is challenging, the identification and targeting of upstream regulators of HSF1 presents a tractable alternative strategy. Here we demonstrate that in triple negative breast cancer (TNBC) cells, the dual-specificity tyrosine-regulated kinase 2 (DYRK2) phosphorylates HSF1, promoting its nuclear stability and transcriptional activity. Thus, DYRK2 depletion reduces HSF1 activity and sensitises TNBC cells to proteotoxic stress. Importantly, in tumours from TNBC patients, DYRK2 levels positively correlate with active HSF1 and associates with poor prognosis, suggesting that DYRK2 could be promoting TNBC. In agreement with this, DYRK2 depletion reduces tumour growth in a TNBC xenograft model. These findings identify DYRK2 as both, a key modulator of the HSF1 transcriptional program, and a potential therapeutic target.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer
Y. Liang, Y. Wang, … Q. Yang·Cell Death & DiseasePeer-reviewed·Jul 15, 2023
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity
D. Biswas, L. Slade, … T. Pulinilkunnil·bioRxiv·May 18, 2021
- ZHX2 Promotes HIF1α Oncogenic Signaling in Triple-Negative Breast Cancer
- Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers
K. Komurov, N. Singh, L. Privette-Vinnedge·bioRxiv·Aug 18, 2021
- Combined agonism and antagonism of canonical and non-canonical progesterone receptors in triple-negative breast cancer cells potentiates cytotoxicity enhanced by PI3K inhibition
Paula E. Petrella, Jason W. Chen, Benjamin D. Cosgrove·bioRxiv·Jun 26, 2026
- The Cyclin-Like Protein Spy1 Mediates Tumourigenic Potential of Triple Negative Breast Cancer
Bre‐Anne Fifield, Claudia Pecoraro, … Lisa Ann Porter·bioRxiv·Mar 11, 2024